{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:47:19Z","timestamp":1785415639128,"version":"3.56.0"},"reference-count":59,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Many clinicians perceive intravenous (IV) antibiotics as inherently more effective than their oral counterparts. However, randomised controlled trials (RCTs) have demonstrated that oral antibiotics are clinically equivalent to IV antibiotics for many severe bacterial infections. This includes pneumonia, skin and soft tissue infections, pyelonephritis, intra-abdominal infections, osteoarticular infections, bacteraemia and infective endocarditis. When clinically appropriate, oral treatment is more patient-friendly, cost-effective and environmentally friendly. But we still use the IV route much more than necessary. To address a historical practice that is often unwarranted, this\u00a0Therapeutics Letter\u00a0reviews evidence from RCTs and compares the advantages and disadvantages of oral and IV antibiotics. We suggest criteria to determine when oral therapy is appropriate.<\/jats:p>","DOI":"10.4102\/phcfm.v17i1.5282","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:57:05Z","timestamp":1765526225000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral versus intravenous antibiotics: Oral antibiotics are more cost-effective and may be safer than intravenous antibiotics for most infections in stable adults"],"prefix":"10.4102","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9407-4261","authenticated-orcid":false,"given":"Davie","family":"Wong","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-4206","authenticated-orcid":false,"given":"Thomas","family":"Perry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Davar K, Clark D, Centor RM, et al. Can the future of ID escape the inertial dogma of its past? The exemplars of shorter is better and oral is the new IV. Open Forum Infect Dis. 2023;10(1):ofac706. https:\/\/doi.org\/10.1093\/ofid\/ofac706","DOI":"10.1093\/ofid\/ofac706"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax. 2009;64 Suppl 3:iii1\u2013iii55. https:\/\/doi.org\/10.1136\/thx.2009.121434","DOI":"10.1136\/thx.2009.121434"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wald-Dickler N, Holtom PD, Phillips MC, et al. Oral is the new IV. Challenging decades of blood and bone infection dogma: A systematic review. Am J Med. 2022;135(3):369.e1\u201379.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2021.10.007","DOI":"10.1016\/j.amjmed.2021.10.007"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kaasch AJ, L\u00f3pez-Cort\u00e9s LE, Rodr\u00edguez-Ba\u00f1o J, et al. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): An international, open-label, parallel-group, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2024;24(5):523\u2013534. https:\/\/doi.org\/10.1016\/S1473-3099(23)00756-9","DOI":"10.1016\/S1473-3099(23)00756-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mourad A, Nwafo N, Skalla L, et al. Oral versus intravenous antibiotic therapy for Staphylococcus aureus bacteremia or endocarditis: A systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis. 2025;80(1):29\u201336. https:\/\/doi.org\/10.1093\/cid\/ciae476","DOI":"10.1093\/cid\/ciae476"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Omrani AS, Abujarir SH, Ben Abid F, et al. Switch to oral antibiotics in Gram-negative bacteraemia: A randomized, open-label, clinical trial. Clin Microbiol Infect. 2024;30(4):492\u2013498. https:\/\/doi.org\/10.1016\/j.cmi.2023.10.014","DOI":"10.1016\/j.cmi.2023.10.014"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425\u2013436. https:\/\/doi.org\/10.1056\/NEJMoa1710926","DOI":"10.1056\/NEJMoa1710926"},{"key":"ref7","unstructured":"Larrazabal Jr, RB, Chiu HHC, Arcegono MS, Abad CLR. Oral versus intravenous antibiotic treatment for osteomyelitis in adults: A systematic review and meta-analysis. Philipp J Intern Med. 2020;58(4):146\u2013153."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sendi P, Lora-Tamayo J, Cortes-Penfield NW, U\u00e7kay I. Early switch from intravenous to oral antibiotic treatment in bone and joint infections. Clin Microbiol Infect. 2023;29(9):1133\u20131138. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.008","DOI":"10.1016\/j.cmi.2023.05.008"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: A prospective randomized clinical trial. Archiv Intern Med. 1999;159(1):53\u201358. https:\/\/doi.org\/10.1001\/archinte.159.1.53","DOI":"10.1001\/archinte.159.1.53"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Molton JS, Chan M, Kalimuddin S, et al. Oral vs intravenous antibiotics for patients with Klebsiella pneumoniae liver abscess: A randomized, controlled noninferiority study. Clin Infect Dis. 2020;71(4):952\u2013959. https:\/\/doi.org\/10.1093\/cid\/ciz881","DOI":"10.1093\/cid\/ciz881"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dalen D, Fry A, Campbell SG, et al. Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: A double-blind, non-inferiority, randomised controlled trial. Emerg Med J. 2018;35(8):492\u2013498. https:\/\/doi.org\/10.1136\/emermed-2017-207420","DOI":"10.1136\/emermed-2017-207420"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Brindle R, Williams OM, Barton E, Featherstone P. Assessment of antibiotic treatment of cellulitis and erysipelas: A systematic review and meta-analysis. JAMA Dermatol. 2019;155(9):1033\u20131040. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0884","DOI":"10.1001\/jamadermatol.2019.0884"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Erard V, Lamy O, Bochud PY, et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2004;23(2):82\u201388. https:\/\/doi.org\/10.1007\/s10096-003-1060-x","DOI":"10.1007\/s10096-003-1060-x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Teng GL, Chi JY, Zhang HM, et al. Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. J Glob Antimicrob Resist. 2023;32:88\u201397. https:\/\/doi.org\/10.1016\/j.jgar.2022.12.010","DOI":"10.1016\/j.jgar.2022.12.010"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Vidal L, Ben dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev. 2013;2013(10):CD003992. https:\/\/doi.org\/10.1002\/14651858.CD003992.pub3","DOI":"10.1002\/14651858.CD003992.pub3"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415\u2013424. https:\/\/doi.org\/10.1056\/NEJMoa1808312","DOI":"10.1056\/NEJMoa1808312"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Barda B, Schindler C, Bernasconi E, Bongiovanni M. Breaking the dogma of intravenous treatment for infective endocarditis: A systematic review and meta-analysis. J Clin Med. 2024;13(24): 7518. https:\/\/doi.org\/10.3390\/jcm13247518","DOI":"10.3390\/jcm13247518"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-year outcomes of the Partial Oral Treatment of Endocarditis (POET) trial. N Engl J Med. 2022;386(6):601\u2013602. https:\/\/doi.org\/10.1056\/NEJMc2114046","DOI":"10.1056\/NEJMc2114046"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004;53(2):335\u2013344. https:\/\/doi.org\/10.1093\/jac\/dkh088","DOI":"10.1093\/jac\/dkh088"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: A randomized non-inferiority trial. J Antimicrob Chemother. 2015;70(2):581\u2013586. https:\/\/doi.org\/10.1093\/jac\/dku397","DOI":"10.1093\/jac\/dku397"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u2013e195. https:\/\/doi.org\/10.1093\/cid\/ciw376","DOI":"10.1093\/cid\/ciw376"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Landersdorfer CB, Gwee A, Nation RL. Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: Are barriers real or simply perceived? Clin Microbiol Infect. 2023;29(9):1120\u20131125. https:\/\/doi.org\/10.1016\/j.cmi.2023.04.009","DOI":"10.1016\/j.cmi.2023.04.009"},{"key":"ref23","unstructured":"Spellberg B. Oral antibiotic RCTs [homepage on the Internet]. [cited 2025 Jan 27]. Available from: https:\/\/www.bradspellberg.com\/oral-antibiotics"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Reijnders TDY, Saris A, Schultz MJ, Van der Poll T. Immunomodulation by macrolides: Therapeutic potential for critical care. Lancet Respir Med. 2020;8(6):619\u2013630. https:\/\/doi.org\/10.1016\/S2213-2600(20)30080-1","DOI":"10.1016\/S2213-2600(20)30080-1"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Phillips MC, Wald-Dickler N, Davar K, et al. Choosing patients over placebos: Oral transitional therapy vs. IV-only therapy for bacteraemia and infective endocarditis. Clin Microbiol Infect. 2023;29(9):1126\u20131132. https:\/\/doi.org\/10.1016\/j.cmi.2023.04.030","DOI":"10.1016\/j.cmi.2023.04.030"},{"key":"ref26","unstructured":"Lee K, Mercuro N. If the gut works, use it! Five important considerations when switching from IV to PO antibiotics [homepage on the Internet]. [cited 2025 Apr 1]. Available from: https:\/\/www.idstewardship.com\/gut-works-use-five-important-considerations-switching-iv-po-antibiotics\/"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kaal AG, Roos R, De Jong P, et al. Oral versus intravenous antibiotic treatment of moderate-to-severe community-acquired pneumonia: A propensity score matched study. Sci Rep. 2024;14(1): 8271. https:\/\/doi.org\/10.1038\/s41598-024-59026-2","DOI":"10.1038\/s41598-024-59026-2"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gariani K, Pham TT, Kressmann B, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, noninferiority pilot trial. Clin Infect Dis. 2021;73(7):e1539\u2013e1545. https:\/\/doi.org\/10.1093\/cid\/ciaa1758","DOI":"10.1093\/cid\/ciaa1758"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Van Den Broek AK, Visser CE, Veenstra J, et al. The effect of the acute phase of infection on absorption of and exposure to orally administered antibiotics in non-critically ill, hospitalized patients. J Antimicrob Chemother. 2023;78(2):389\u2013396. https:\/\/doi.org\/10.1093\/jac\/dkac401","DOI":"10.1093\/jac\/dkac401"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Meyer NJ, Prescott HC. Sepsis and septic shock. N Engl J Med. 2024;391(22):2133\u20132146. https:\/\/doi.org\/10.1056\/NEJMra2403213","DOI":"10.1056\/NEJMra2403213"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Borek AJ, Ledda A, Pouwels KB, et al. Stop antibiotics when you feel better? Opportunities, challenges and research directions. JAC Antimicrob Resist. 2024;6(5):dlae147. https:\/\/doi.org\/10.1093\/jacamr\/dlae147","DOI":"10.1093\/jacamr\/dlae147"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Archiv Intern Med. 2004;164(15):1669\u20131674. https:\/\/doi.org\/10.1001\/archinte.164.15.1669","DOI":"10.1001\/archinte.164.15.1669"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Wake RM, Molloy SF, Jarvis JN, et al. Cryptococcal antigenemia in advanced human immunodeficiency virus disease: Pathophysiology, epidemiology, and clinical implications. Clin Infect Dis. 2023;76(4):764\u2013770. https:\/\/doi.org\/10.1093\/cid\/ciac675","DOI":"10.1093\/cid\/ciac675"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Markham JL, Goldman JL. To discharge or not to discharge on outpatient parenteral antimicrobial therapy: That is the question. Hosp Pediatr. 2019;9(4):314\u2013316. https:\/\/doi.org\/10.1542\/hpeds.2018-0279","DOI":"10.1542\/hpeds.2018-0279"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Spivak ES, Kendall B, Orlando P, et al. Evaluation of outpatient parenteral antimicrobial therapy at a Veterans Affairs hospital. Infect Control Hosp Epidemiol. 2015;36(9):1103\u20131105. https:\/\/doi.org\/10.1017\/ice.2015.131","DOI":"10.1017\/ice.2015.131"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wang X, Wu D, Xuan Z, et al. The influence of a ban on outpatient intravenous antibiotic therapy among the secondary and tertiary hospitals in China. BMC Public Health. 2020;20(1): 1794. https:\/\/doi.org\/10.1186\/s12889-020-09948-z","DOI":"10.1186\/s12889-020-09948-z"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr. 2020;43(2):45\u201348. https:\/\/doi.org\/10.18773\/austprescr.2020.008","DOI":"10.18773\/austprescr.2020.008"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Dlamini NN, Meyer JC, Kruger D, et al. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. Hosp Pract. 2019;47(2):88\u201395. https:\/\/doi.org\/10.1080\/21548331.2019.1592880","DOI":"10.1080\/21548331.2019.1592880"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Dulku M, Sekhon T, Tejani AM. Assessment of Intravenous versus Oral Antimicrobials in a Large Regional Health Authority. Can J Hosp Pharm. 2022;75(2):108\u2013112. https:\/\/doi.org\/10.4212\/cjhp.v75i2.3173","DOI":"10.4212\/cjhp.v75i2.3173"},{"key":"ref40","unstructured":"Wong D. The unsubstantiated preference for outpatient IV antibiotics. BCMJ [serial online]. 2025;67(1):28\u201331. [cited 2025 Jan 27]. Available from: https:\/\/bcmj.org\/articles\/unsubstantiated-preference-outpatient-iv-antibiotics"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Jenkins A. IV to oral switch: A novel viewpoint. J Antimicrob Chemother. 2023;78(10):2603\u20132604. https:\/\/doi.org\/10.1093\/jac\/dkad239","DOI":"10.1093\/jac\/dkad239"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents. 2020;55(1):105769. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.020","DOI":"10.1016\/j.ijantimicag.2019.07.020"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"McMeekin N, Geue C, Briggs A, et al. Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: Evidence from a non-inferiority trial. Wellcome Open Res. 2019;4:108. https:\/\/doi.org\/10.12688\/wellcomeopenres.15314.4","DOI":"10.12688\/wellcomeopenres.15314.2"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Walpole SC, Eii MN, Lyons T, Aldridge C. Improving antimicrobial use to protect the environment: What is the role of infection specialists? Antibiotics. 2023;12(4):640. https:\/\/doi.org\/10.3390\/antibiotics12040640","DOI":"10.3390\/antibiotics12040640"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Eii MN, Walpole S, Aldridge C. Sustainable practice: Prescribing oral over intravenous medications. BMJ. 2023;383:e075297. https:\/\/doi.org\/10.1136\/bmj-2023-075297","DOI":"10.1136\/bmj-2023-075297"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27(1):19\u201334. https:\/\/doi.org\/10.1016\/j.ccc.2010.09.006","DOI":"10.1016\/j.ccc.2010.09.006"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Westbrook JI, Li L, Woods A, et al. Risk factors associated with medication administration errors in children: A prospective direct observational study of paediatric inpatients. Drug Saf. 2024;47(6):545\u2013556. https:\/\/doi.org\/10.1007\/s40264-024-01408-6","DOI":"10.1007\/s40264-024-01408-6"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Krein SL, Saint S, Trautner BW, et al. Patient-reported complications related to peripherally inserted central catheters: A multicentre prospective cohort study. BMJ Qual Saf. 2019;28(7):574\u2013581. https:\/\/doi.org\/10.1136\/bmjqs-2018-008726","DOI":"10.1136\/bmjqs-2018-008726"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Bamford KB, Desai M, Aruede MJ, et al. Patients\u2019 views and experience of intravenous and oral antimicrobial therapy: Room for change. Injury. 2011;42 Suppl 5:S24\u2013S27. https:\/\/doi.org\/10.1016\/S0020-1383(11)70129-2","DOI":"10.1016\/S0020-1383(11)70129-2"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Taylor PC, Betteridge N, Brown TM, et al. Treatment mode preferences in rheumatoid arthritis: Moving toward shared decision-making. Patient Prefer Adherence. 2020;14:119\u2013131. https:\/\/doi.org\/10.2147\/PPA.S220714","DOI":"10.2147\/PPA.S220714"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature. Patient Prefer Adherence. 2016;10:1609\u20131621. https:\/\/doi.org\/10.2147\/PPA.S106629","DOI":"10.2147\/PPA.S106629"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Li HK, Agweyu A, English M, Bejon P. An unsupported preference for intravenous antibiotics. PLoS Med. 2015;12(5):e1001825. https:\/\/doi.org\/10.1371\/journal.pmed.1001825","DOI":"10.1371\/journal.pmed.1001825"},{"key":"ref53","unstructured":"Canadian Society of Internal Medicine. Nineteen tests and treatments to question [homepage on the Internet]. Choosing Wisely Canada; 2024. [cited 2025 Apr 1]. https:\/\/choosingwiselycanada.org\/recommendation\/internal-medicine\/"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Spellberg B, Aggrey G, Brennan MB, et al. Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: A WikiGuidelines group consensus statement. JAMA Netw Open. 2022;5(5):e2211321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.11321","DOI":"10.1001\/jamanetworkopen.2022.11321"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"McDonald EG, Aggrey G, Aslan AT, et al. Guidelines for diagnosis and management of infective endocarditis in adults: A WikiGuidelines group consensus statement. JAMA Netw Open. 2023;6(7):e2326366. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26366","DOI":"10.1001\/jamanetworkopen.2023.26366"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Waibel F, Berli M, Catanzaro S, et al. Optimization of the antibiotic management of diabetic foot infections: Protocol for two randomized controlled trials. Trials. 2020;21(1):54. https:\/\/doi.org\/10.1186\/s13063-019-4006-z","DOI":"10.1186\/s13063-019-4006-z"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"De Kretser D, Mora J, Bloomfield M, et al. Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) trial early oral switch protocol. Clin Infect Dis. 2024;79(4):871\u2013887. https:\/\/doi.org\/10.1093\/cid\/ciad666","DOI":"10.1093\/cid\/ciad666"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Munting A, Van Singer M, Boillat-Blanco N. Standing on the Shoulders of Imperfect Humans: From IV dogma to oral antibiotic therapy for bone and joints infection. CMI Commun. 2025;2(3):105088. https:\/\/doi.org\/10.1016\/j.cmicom.2025.105088","DOI":"10.1016\/j.cmicom.2025.105088"}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:57:30Z","timestamp":1765526250000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/5282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v17i1.5282","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"article-number":"a5282"}}